A Novel Prognostic Scoring Model for Myelodysplastic Syndrome Patients With SF3B1 Mutation
Liya Ma, Bin Liang, Huixian Hu, Wenli Yang et al. • Frontiers in Oncology
(2022)
The outcomes of myelodysplastic syndrome (MDS) patients with SF3B1 mutation, despite identified as a favorable prognostic biomarker, are variable. To comprehend the heterogeneity in clinical characteristics and outcomes, we reviewed 140 MDS...
DOAJ
Open Access (DOAJ)
DOI:
10.3389/fonc.2022.905490